[1] |
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
[2] |
郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231.
|
|
ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol, 2024, 46(3): 221-231.
|
[3] |
吴梦吟, 顾凯, 吴春晓, 等. 1973—2017年上海市结直肠癌流行趋势及年龄-时期-队列分析[J]. 肿瘤, 2023, 43(4): 325-336.
|
|
WU M Y, GU K, WU C X, et al. Colorectal cancer incidence and mortality trends in urban Shanghai, China from 1973 to 2017: a Joinpoint regression and age-period-cohort analysis[J]. Tumor, 2023, 43(4): 325-336.
|
[4] |
郑莹, 龚杨明, 顾凯, 等. 上海市社区居民结直肠癌筛查项目[J]. 上海预防医学, 2016, 28(10): 739-742.
|
|
ZHENG Y, GONG Y M, GU K, et al. Shanghai community resident colorectal cancer screening program[J]. Shanghai J Prev Med, 2016, 28(10): 739-742.
|
[5] |
杨群娣, 鲍萍萍, 郑杨, 等. 公共卫生视角下的《上海市防治慢性非传染性疾病中长期规划(2018—2030年)》[J]. 上海预防医学, 2020, 32(6): 487-491.
|
|
YANG Q D, BAO P P, ZHENG Y, et al. “Medium and long-term plan for the prevention and control of chronic non-communicable diseases in Shanghai (2018-2030)” in the perspective of public health[J]. Shanghai J Prev Med, 2020, 32(6): 487-491.
|
[6] |
吴春晓, 顾凯, 施燕, 等. 肿瘤命名与编码[M]. 上海: 上海科学普及出版社, 2022.
|
|
WU C X, GU K, SHI Y, et al. Tumor nomenclature and coding[M]. Shanghai: Shanghai Popular Science Publishing House, 2022.
|
[7] |
KURIHARA M, SEGI M. Cancer mortality for selected sites in 24 countries[M]. Sendai: Tohoku University School of Medicine, 1960.
|
[8] |
KIM H J, FAY M P, FEUER E J, et al. Permutation tests for Joinpoint regression with applications to cancer rates[J]. Stat Med, 2000, 19(3): 335-351.
doi: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z
pmid: 10649300
|
[9] |
GONG Y M, PENG P, BAO P P, et al. The implementation and first-round results of a community-based colorectal cancer screening program in Shanghai, China[J]. Oncologist, 2018, 23(8): 928-935.
doi: 10.1634/theoncologist.2017-0451
pmid: 29540604
|
[10] |
窦剑明, 叶景虹, 庞怡, 等. 2013—2015年上海市结直肠癌筛查队列病例诊断特征和生存分析[J]. 肿瘤, 2023, 43(4): 337-346.
|
|
DOU J M, YE J H, PANG Y, et al. Diagnostic characteristics and survival analysis of screen-detected colorectal cancer in Shanghai, 2013-2015[J]. Tumor, 2023, 43(4): 337-346.
|
[11] |
赵丽中, 王秋伟, 于紫婷, 等. 2012—2022年天津市结直肠癌筛查结果分析[J]. 中国肿瘤, 2023, 32(9): 669-675.
|
|
ZHAO L Z, WANG Q W, YU Z T, et al. Analysis of colorectal cancer screening results in Tianjin from 2012 to 2022[J]. China Cancer, 2023, 32(9): 669-675.
|
[12] |
曹泮悬, 沈永洲, 黄彦钦, 等. 浙江省海宁市40-74岁目标人群结直肠癌早诊早治筛查结果分析[J]. 中国肿瘤, 2017, 26(3): 181-184.
|
|
CAO P X, SHEN Y Z, HUANG Y Q, et al. Early diagnosis and early treatment of colorectal cancer in the target population of 40-74 years old in Haining city[J]. China Cancer, 2017, 26(3): 181-184.
|
[13] |
杜倩, 邵春昕, 邹赤群, 等. 2015—2021年北京市通州区结直肠癌早诊早治筛查结果分析[J]. 中国肿瘤, 2023, 32(9): 698-702.
|
|
DU Q, SHAO C X, ZOU C Q, et al. Analysis of screening results of colorectal cancer in Tongzhou district of Beijing, 2015: 2021[J]. China Cancer, 2023, 32(9): 698-702.
|
[14] |
李科, 梁颖茹, 秦鹏哲, 等. 2015—2018年广州市40-74岁社区人群试点结直肠癌筛查结果分析[J]. 中国肿瘤, 2023, 32(1): 39-45.
|
|
LI K, LIANG Y R, QIN P Z, et al. Results of colorectal cancer screening among communitiy-dwelling residents aged 40-74 years in pilot areas of Guangzhou municipality from 2015 to 2018[J]. China Cancer, 2023, 32(1): 39-45.
|
[15] |
师苗苗, 梁迪, 师金, 等. 2016—2022年河北省城市地区结直肠癌筛查和随访结果分析[J]. 中国肿瘤, 2023, 32(6): 423-430.
|
|
SHI M M, LIANG D, SHI J, et al. Results of colorectal cancer screening and follow-up in urban areas of Hebei province from 2016 to 2022[J]. China Cancer, 2023, 32(6): 423-430.
|
[16] |
陈赞广, 雷林, 林铠浩, 等. 2017—2021年广东省深圳市城市居民结直肠癌风险评估及筛查结果分析[J]. 华南预防医学, 2023, 49(7): 891-895.
|
|
CHEN Z G, LEI L, LIN K H, et al. Colorectal cancer risk assessment and screening results for urban residents of Shenzhen, Guangdong, 2017-2021[J]. South China J Prev Med, 2023, 49(7): 891-895.
|
[17] |
KNUDSEN A B, ZAUBER A G, RUTTER C M, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US preventive services task force[J]. JAMA, 2016, 315(23): 2595-2609.
doi: 10.1001/jama.2016.6828
pmid: 27305518
|
[18] |
CARDOSO R, GUO F, HEISSER T, et al. Proportion and stage distribution of screen-detected and non-screen-detected colorectal cancer in nine European countries: an international, population-based study[J]. Lancet Gastroenterol Hepatol, 2022, 7(8): 711-723.
|
[19] |
DASGUPTA P, CAMERON J K, GOODWIN B, et al. Geographical and spatial variations in bowel cancer screening participation, Australia, 2015-2020[J]. PLoS One, 2023, 18(7): e0288992.
|
[20] |
JIN P, WU Z T, LI S R, et al. Colorectal cancer screening with fecal occult blood test: a 22-year cohort study[J]. Oncol Lett, 2013, 6(2): 576-582.
pmid: 24137374
|
[21] |
CARDOSO R, GUO F, HEISSER T, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study[J]. Lancet Oncol, 2021, 22(7): 1002-1013.
doi: 10.1016/S1470-2045(21)00199-6
pmid: 34048685
|
[22] |
沈永洲, 黄彦钦, 祝丽娟, 等. 海宁市32万余结直肠癌筛查目标人群回顾性队列研究[J]. 中华肿瘤杂志, 2015, 37(4): 317-320.
|
|
SHEN Y Z, HUANG Y Q, ZHU L J, et al. A retrospective cohort study of 320 thousand subjects of colorectal cancer screening in Haining City[J]. Chin J Oncol, 2015, 37(4): 317-320.
|
[23] |
KLIMKIEWICZ P. USPSTF colorectal cancer screening update 2021: a review of evidence[J]. Nurse Pract, 2022, 47(12): 37-42.
doi: 10.1097/01.NPR.0000884892.06046.34
pmid: 36399147
|
[24] |
Australian Institute of Health and Welfare, HEALTH A G D O. Analysis of colorectal cancer outcomes for the Australian national bowel cancer screening program[J]. Asia Pac J Clin Oncol, 2016, 12(1): 22-32.
|
[25] |
PARENTE F, VAILATI C, BOEMO C, et al. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy[J]. Dig Liver Dis, 2015, 47(1): 68-72.
|